Thuy Tram Tran
Nurse Practitioner · Westminster, CANPI 1831589837
Payments from drug & device makers
Across 251 payments — averaging $35.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AstraZeneca$1K
- Lilly USA, LLC$974
- Bayer$802
- Gilead$481
- GSK$461
- plus $2K from 21 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$8,874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 51 | $2,669 |
| AstraZeneca | 21 | $1,097 |
| Lilly USA, LLC | 24 | $974 |
| Bayer | 43 | $802 |
| Gilead | 19 | $481 |
| GSK | 11 | $461 |
| Johnson & Johnson(2 entities) | 7 | $271 |
| Novo Nordisk | 8 | $263 |
| Merck | 14 | $255 |
| AbbVie | 9 | $236 |
| Astellas Pharma US Inc | 4 | $183 |
| Redhill Biopharma Inc. | 4 | $159 |
| Vanda Pharmaceuticals Inc. | 6 | $157 |
| Boehringer Ingelheim | 2 | $148 |
| Amarin Pharma, Inc. | 6 | $137 |
| Pfizer | 6 | $126 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Novartis | 2 | $53 |
| Exact Sciences | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Seqirus USA Inc | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Eisai Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,880 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 87 | $145,555 |
| JardianceEmpagliflozin | 83 | $77,567 |
| RybelsusSemaglutide | 45 | $76,907 |
| VascepaIcosapent Ethyl | 124 | $73,722 |
| KerendiaFinerenone | 63 | $71,746 |
| TradjentaLinagliptin | 78 | $69,744 |
| JanuviaSitagliptin Phosphate | 54 | $64,631 |
| EliquisApixaban | 59 | $60,662 |
| RestasisCyclosporine | 64 | $52,087 |
| LinzessLinaclotide | 61 | $46,901 |
| MyrbetriqMirabegron | 49 | $37,960 |
| Cyclosporine | 100 | $33,361 |
| OzempicSemaglutide | 30 | $30,250 |
| Diclofenac Sodium | 152 | $25,675 |
| VemlidyTenofovir Alafenamide | 15 | $20,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $148 | $147,311161 claims |
| AmgenProlia | $2,669 | $145,55587 claims |
| Novo NordiskRybelsus, Ozempic | $263 | $107,15775 claims |
| AbbVieRestasis, Linzess | $236 | $98,988125 claims |
| BayerKerendia | $802 | $71,74663 claims |
| MerckJanuvia | $255 | $64,63154 claims |
| PfizerEliquis | $126 | $60,66259 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $37,96049 claims |
| GileadVemlidy | $481 | $20,93715 claims |
| GSKTrelegy Ellipta | $461 | $17,80414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Westminster
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.